Clinical trial NCT00005840: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Official title: Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Stage III Uterine Corpus Cancer
Stage IV Uterine Corpus Cancer
Lead sponsor: GOG Foundation
Sponsor class: NETWORK
Collaborators: name: National Cancer Institute (NCI)
First posted: 2003-01-27
Enrollment: 35
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase I trial is studying the side effects and best dose of combination chemotherapy when given with radiation therapy in treating patients with stage III or stage IV endometrial cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.

Detailed description: OBJECTIVES:

I. Determine the safety and maximum tolerated doses of paclitaxel and cisplatin when administered with radiotherapy in patients with stage III or IV endometrial cancer.

II. Assess the time to disease progression and overall survival of patients treated with this regimen.

OUTLINE: This is a dose-escalation study of paclitaxel and cisplatin.

Patients receive paclitaxel IV over 1 hour and cisplatin IV on days 1, 8, 15, 22, 29, and 36. Patients also undergo whole abdominal radiotherapy for 5 consecutive days weekly for 6 weeks.

Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 3-48 patients will be accrued for part I and 14-20 patients will be accrued for part II of this study.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed surgical stage III or IV endometrial cancer
* Any stage clear or serous papillary endometrial cancer
* Positive para-aortic lymph nodes allowed
* Tumor must be surgically reduced to 2 cm or less within 8 weeks of study

  * Must have had hysterectomy and bilateral salpingo-oophorectomy
* No recurrent disease
* No metastases to lung or liver parenchyma or inguinal or scalene lymph nodes
* Performance status - GOG 0-2
* Absolute neutrophil count greater than 2,000/mm\^3
* Platelet count at least 100,000/mm\^3
* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* SGOT no greater than 3 times ULN
* Creatinine no greater than 1.5 times ULN
* No other prior or concurrent malignancy in the past 5 years except non-melanoma skin cancer
* No prior chemotherapy
* No prior radiotherapy
* See Disease Characteristics
* No more than 8 weeks since prior surgery
* No prior anticancer therapy that would preclude study

Primary outcomes:
measure: Acute toxicity for identification of MTD, using the 21 major categories of the Cancer Therapy Evaluation Program Common Toxicity Criteria (CTEP CTC) v2.0
timeFrame: Up to 30 days post-radiotherapy
measure: Chronic toxicity based on the NCI CTC Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity scoring scheme
timeFrame: Up to 6 months post-radiotherapy
Secondary outcomes:
measure: Number of dose level combinations that will have been evaluated prior to MTD establishment
timeFrame: Up to 60 months
measure: Site (local/distant) of treatment failure
timeFrame: Up to 5 years
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Gynecologic Oncology Group
state: Pennsylvania
Study officials:
affiliation: Gynecologic Oncology Group
name: D. McMeekin
role: PRINCIPAL_INVESTIGATOR
References: